MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals is set for success with their highly anticipated drug candidates, Livmarli and Brelovitug, in the rare liver disease market. With no FDA-approved treatments available for conditions such as progressive familial intrahepatic cholestasis (PFIC), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC), there is a significant unmet need and Mirum is well-positioned to fill this gap. Their expanding pipeline, recent acquisitions, and positive clinical data for their lead candidates demonstrate the company's potential for growth and future profitability.

Mirum Pharmaceuticals is facing a negative outlook as several catalysts in the next few years may not be strong enough to drive significant growth for the company. While their product Livmarli has been approved and could potentially generate revenue, the upcoming data for MRM-3379’s BLOOM study and Volixbat VISTAS may not have a significant impact on the stock price. Additionally, while interim results from brelovitug's AZURE-1 study show a favorable profile, the small market opportunity for HDV may not be enough to significantly drive revenue for the company.